Business Wire

ADVA

8.10.2019 09:02:06 CEST | Business Wire | Press release

Share
ADVA brings sub-microsecond synchronization to utility and broadcast networks

ADVA (FSE: ADV) today announced that it has extended the capabilities of its compact Oscilloquartz PTP timing technology to enable power utility and broadcast networks to achieve sub-microsecond synchronization. Now electricity companies can harness the accuracy needed for smart power grids, and media enterprises can meet key timing challenges. The two upgraded solutions are the pluggable OSA 5401 , the market’s smallest PTP grandmaster clock, and the highly versatile OSA 5405 , an integrated PTP grandmaster with dual GNSS antenna and receiver. Both technologies have proved critical in the telecommunications industry, where they have been widely deployed across the globe. They offer outstanding precision and unrivaled design density. Thanks to unique spoofing and jamming detection capabilities, they also provide unbeatable availability.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191008005048/en/

“This upgrade is big news for utility and media network operators looking to harness the most advanced innovation in their field. With our OSA 5401 and 5405 bringing new levels of accuracy and resilience to their infrastructure, they can reap the benefits of emerging bandwidth-intensive, latency-sensitive applications,” said Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. “These devices are feature rich and incredibly efficient. But as well as their versatility, what really sets them apart is their extremely small footprint and low power consumption. This is key to bringing packet time distribution to the edge of network. With our technology ensuring sub-microsecond synchronization, smart grids can perform flexible, real-time decision making, as well as monitoring and automated maintenance. And for media companies, the possibilities for high-quality, interactive broadcasting from any location are enormous.”

The OSA 5401 and OSA 5405 now comply with the latest PTP profiles for time, frequency and phase synchronization in both power utility and broadcast networks . These include the IEC/IEEE 61850-9-3 Power Utility Profile for precise time distribution and clock synchronization in electrical grids with an accuracy of 1μs, and SMPTE 2059 for synchronizing video and audio equipment over packet networks. By supporting NTP, both solutions also enable enterprises to run an on-premises NTP server for high levels of accuracy and uncompromised availability. What’s more, the OSA 5401 and OSA 5405 include advanced GNSS jamming and spoofing detection mechanisms, which are integrated in a centralized AI-based GNSS assurance toolkit.

Taking up zero real estate and using very little power, the OSA 5401 can be deployed in the most space-restrictive locations. Its capabilities include multi-constellation GNSS (GPS/GLONASS/BEIDOU) and accurate time and frequency recovery, even in challenging environments such as urban canyons. Available in both indoor and outdoor variants, the OSA 5405 radically simplifies and extends the reach of GNSS antenna installation by allowing operators to forget about archaic and expensive RF cables and instead use simple Ethernet over copper cables or optical fiber. With the OSA 5405, highly precise GNSS-sourced synchronization is supported by network-based SyncE and PTP backups for highly stable sub-microsecond timing accuracy.

“Our mission is to make precise, resilient and affordable timing available in every industry. Both our OSA 5401 and OSA 5405 have had a significant impact on communication service provider networks, supporting mass small cell rollout and the transition to 5G connectivity. Now we’re ready to bring accurate, reliable and cost-efficient PTP timing to the edge of power and broadcast networks,” commented Ulrich Kohn, director, technical marketing, ADVA. “One feature of these devices that will prove key to network operators in these industries is their unique spoofing and jamming detection capabilities. These work on two layers. Firstly, network elements identify disruption autonomously. Then, on top of that, a layer powered by AI analyzes information from multiple devices. Using machine learning, this delivers the highly sophisticated and extremely robust protection needed for machine type communication applications in energy grid protection and control.”

Further information can be found in these slides: https://adva.li/power-and-broadcast-slides .

A supporting solution brief is also available: https://adva.li/broadcast-solution-brief .


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to- end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA Optical Networking company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye